 |
 |
 |
 |
NewsApril 23rd, 2013Teva and Xenon Announce FDA Orphan Drug Designation for Pain Drug XEN402 Jerusalem, Israel, and Burnaby, British Columbia, (April 23, 2013) – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that the US Food and Drug... read more > April 22nd, 2013 Xenon Named Company of the Year by BIOTECanada Vancouver, Canada (April 22, 2013) – Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada’s Gold Leaf Company of the Year Award for 2013. The... read more > April 17th, 2013 Xenon Exclusively Licenses to Merck Compounds for a Novel Target for Cardiovascular Disease Vancouver, Canada (April 17, 2013) – Xenon announced that Merck, known as MSD outside the United States and Canada, through an affiliate, has exercised its option to exclusively license... read more > April 8th, 2013 Xenon Named Life Sciences Company of the Year by LifeSciences British Columbia Vancouver, Canada (April 8th, 2013) – Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded the LifeSciences British Columbia Life Sciences Company of the Year Award... read more > |